Etrolizumab: Additional Phase II data

Additional data from the Phase II EUCALYPTUS trial in 124 patients with moderate-to-severely active UC showed that 20.5% of patients receiving once-monthly 100 mg subcutaneous etrolizumab

Read the full 265 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE